CN107226813A - 一种制备4-溴-1,8-二氮萘的方法 - Google Patents
一种制备4-溴-1,8-二氮萘的方法 Download PDFInfo
- Publication number
- CN107226813A CN107226813A CN201610177446.0A CN201610177446A CN107226813A CN 107226813 A CN107226813 A CN 107226813A CN 201610177446 A CN201610177446 A CN 201610177446A CN 107226813 A CN107226813 A CN 107226813A
- Authority
- CN
- China
- Prior art keywords
- reaction
- naphthridine
- solvent
- temperature
- bromo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims abstract description 9
- 238000005893 bromination reaction Methods 0.000 claims abstract description 10
- 150000001875 compounds Chemical class 0.000 claims abstract description 10
- 238000006722 reduction reaction Methods 0.000 claims abstract description 9
- 230000000977 initiatory effect Effects 0.000 claims abstract description 4
- 239000000463 material Substances 0.000 claims abstract description 4
- 238000007363 ring formation reaction Methods 0.000 claims abstract description 4
- 230000031709 bromination Effects 0.000 claims abstract description 3
- 230000009467 reduction Effects 0.000 claims abstract description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 26
- 238000003786 synthesis reaction Methods 0.000 claims description 26
- 238000006243 chemical reaction Methods 0.000 claims description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 12
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 8
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 7
- 229940126214 compound 3 Drugs 0.000 claims description 7
- 238000010992 reflux Methods 0.000 claims description 6
- 229940125904 compound 1 Drugs 0.000 claims description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 5
- AFCIMSXHQSIHQW-UHFFFAOYSA-N [O].[P] Chemical compound [O].[P] AFCIMSXHQSIHQW-UHFFFAOYSA-N 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- LTMRRSWNXVJMBA-UHFFFAOYSA-L 2,2-diethylpropanedioate Chemical compound CCC(CC)(C([O-])=O)C([O-])=O LTMRRSWNXVJMBA-UHFFFAOYSA-L 0.000 claims description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 3
- 239000003638 chemical reducing agent Substances 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 claims 2
- SEPPVOUBHWNCAW-FNORWQNLSA-N (E)-4-oxonon-2-enal Chemical compound CCCCCC(=O)\C=C\C=O SEPPVOUBHWNCAW-FNORWQNLSA-N 0.000 claims 1
- OGFAWKRXZLGJSK-UHFFFAOYSA-N 1-(2,4-dihydroxyphenyl)-2-(4-nitrophenyl)ethanone Chemical compound OC1=CC(O)=CC=C1C(=O)CC1=CC=C([N+]([O-])=O)C=C1 OGFAWKRXZLGJSK-UHFFFAOYSA-N 0.000 claims 1
- LLBZPESJRQGYMB-UHFFFAOYSA-N 4-one Natural products O1C(C(=O)CC)CC(C)C11C2(C)CCC(C3(C)C(C(C)(CO)C(OC4C(C(O)C(O)C(COC5C(C(O)C(O)CO5)OC5C(C(OC6C(C(O)C(O)C(CO)O6)O)C(O)C(CO)O5)OC5C(C(O)C(O)C(C)O5)O)O4)O)CC3)CC3)=C3C2(C)CC1 LLBZPESJRQGYMB-UHFFFAOYSA-N 0.000 claims 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 1
- PHSPJQZRQAJPPF-UHFFFAOYSA-N N-alpha-Methylhistamine Chemical compound CNCCC1=CN=CN1 PHSPJQZRQAJPPF-UHFFFAOYSA-N 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 claims 1
- 229910052763 palladium Inorganic materials 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 239000012279 sodium borohydride Substances 0.000 claims 1
- 229910000033 sodium borohydride Inorganic materials 0.000 claims 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract 2
- 229910052794 bromium Inorganic materials 0.000 abstract 2
- 150000003930 2-aminopyridines Chemical class 0.000 abstract 1
- 238000009509 drug development Methods 0.000 abstract 1
- 239000002547 new drug Substances 0.000 abstract 1
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 5
- 108091000080 Phosphotransferase Proteins 0.000 description 4
- 102000020233 phosphotransferase Human genes 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000010189 synthetic method Methods 0.000 description 3
- SIADAGFXEHBPGG-UHFFFAOYSA-N 4-chloro-1,8-naphthyridine Chemical compound C1=CC=C2C(Cl)=CC=NC2=N1 SIADAGFXEHBPGG-UHFFFAOYSA-N 0.000 description 2
- 230000004715 cellular signal transduction Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- IYXGSMUGOJNHAZ-UHFFFAOYSA-N Ethyl malonate Chemical class CCOC(=O)CC(=O)OCC IYXGSMUGOJNHAZ-UHFFFAOYSA-N 0.000 description 1
- 102000004195 Isomerases Human genes 0.000 description 1
- 108090000769 Isomerases Proteins 0.000 description 1
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229910019213 POCl3 Inorganic materials 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102000009097 Phosphorylases Human genes 0.000 description 1
- 108010073135 Phosphorylases Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000012296 anti-solvent Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 150000005054 naphthyridines Chemical class 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
本发明公开了一种制备4‑溴‑1,8‑二氮萘的方法，以2‑氨基吡啶为起始原料，经过成环、溴化、还原得到4‑溴‑1,8‑二氮萘，该化合物是新药研发重要的中间体。
Description
技术领域
本发明涉及一种重要医药中间体的制备方法，特别涉及化合物4-氯-1,8-二氮萘及其合成方法。
技术背景
化合物4-氯-1,8-二氮萘，英文化学名为4-chloro-1,8-naphthyridine，CAS：35170-94-6，结构式为：
该化合物是合成萘啶类衍生物的重要中间体。萘啶衍生物通过消耗ATP的蛋白质如激酶进行的信号传导的抑制、调节和/或调控其作用。结合ATP并利用其能量来改变构象、使底物磷酸化和启动信号级联放大的蛋白质已知来自许多类型，如激酶、磷酸酶、侣伴蛋白或异构酶。使用特定的工具和技术可以富集ATP-结合蛋白。作为癌症标志物的机理部分，Ser/Thr激酶和受体酪氨酸激酶是细胞信号传导中必需的磷酸化酶。细胞周期、存活、增值和细胞死亡是由细胞信号传导所调节的细胞过程，以允许组织生长、再生和处于内稳态或退化。因此，一些激酶是哺乳动物治疗的灵敏靶标。在不同的作为人激酶组的组成部分的激酶系列中，受体酪氨酸KDR可以刺激内皮细胞存活和增殖，条件是被VEGF胞外连接。然后，配体结合可以导致胞内磷酸化事件、即信号级联放大，最终导致增殖。
目前，未见有其他专利文献报道该化合物及其合成方法。
发明内容
本发明公开了一种4-氯-1,8-二氮萘的合成方法，以2-氨基吡啶为起始原料，经过成环、溴化、还原三步反应得到4-氯-1,8-二氮萘，该化合物是合成萘啶衍生物的重要中间体。合成步骤如下：
(1)以2-氨基吡啶为起始原料，与丙二酸二乙酯反应得到2，
(2)把2与溴化剂反应，得到3；
(3)把3进行还原，得到4
在一优选的实施方式中，所述的合成化合物1,8-二氮杂萘-2,4-二醇的反应所用的环化试剂选自丙二酸二乙酯；所述的溴化反应合成化合物3所用的溴化剂选自三氯氧磷；所述的还原反应合成4-氯-1,8-二氮萘所用的还原剂选自Pd/C-氢气。
在另一优选的实施方式中，其特征在于,所述的合成化合物1,8-二氮杂萘-2,4-二醇的反应所用溶剂选自四氢呋喃；所述的溴化反应合成化合物3所用的溶剂选自三溴氧磷；所述的还原反应合成4-溴-1,8-二氮萘所用的溶剂选自甲醇。
在再一优选的实施方式中，其特征在于,所述的合成化合物1,8-二氮杂萘-2,4-二醇的反应温度是溶剂的回流温度；所述的溴化反应合成化合物3所用的反应温度是溶剂的回流温度；所述的还原反应合成4-氯-1,8-二氮萘的反应温度是室温。
本发明涉及4-溴-1,8-二氮萘及其合成方法，该化合物是合成合成萘啶衍生物的重要中间体，目前没有其他相关专利文献报道。
下面通过实施例对本发明作进一步的描述，这些描述并不是对本发明内容作进一步的限定。本领域的技术人员应理解，对本发明的技术特征所作的等同替换，或相应的改进，仍属于本发明的保护范围之内。
具体实施例方式
实施例1
(1)1,8-二氮杂萘-2,4-二醇的合成
把17g的2-氨基吡啶、21ml丙二酸二乙酯加入到140ml四氢呋喃中，搅拌，加热，回流4小时，冷却，减压浓缩，剩余物用层析柱分离得到19g产物。
(2)1,8-二氮杂萘-2,4-二溴的合成
把第一步所得产物19g溶于200ml三溴氧磷，加热回流，反应12小时，把反应液倒入冰水中，用乙酸乙酯萃取，有机相用饱和食盐水洗三遍，再用无水硫酸钠干燥，减压浓缩，剩余物用层析柱分离得到产物14g油状物。
(3)4-溴-1,8-二氮萘的合成
把14g 1,8-二氮杂萘-2,4-二氯加入到150ml甲醇中，加入2g 10％Pd/C，通入氢气，室温反应3小时，过滤，收集滤液，浓缩，剩余物用层析柱分离得到产物6.9g。
Claims (5)
1.一种制备4-溴-1,8-二氮萘的方法，以2-氨基吡啶为起始原料，经过成环、溴化、还原三步反应得到4-溴-1,8-二氮萘，合成路线如下：
2.根据权利要求1的方法，其特征在于,所述的合成化合物1,8-二氮杂萘-2,4-二醇的反应所用的环化试剂选自丙二酸二乙酯或丙二酸二甲酯中的一种或两种的混合物；所述的溴化反应合成化合物3所用的溴化剂选自溴化氢、三溴化磷、五溴化磷、三溴氧磷中的一种或几的混合物；所述的还原反应合成4-溴-1,8-二氮萘所用的还原剂选自Pd/C-氢气、氢氧化钯/C-氢气、铁粉、锌粉、硼氢化钠、硼氢化钾中的一种或几种的混合物。
3.根据权利要求1的方法，其特征在于,所述的合成化合物1,8-二氮杂萘-2,4-二醇的反应所用溶剂选自四氢呋喃、N,N-二甲基甲酰胺、甲苯、甲醇、乙醇、正丙醇、异丙醇中的一种或几种的混合物；所述的溴化反应合成化合物3所用的溶剂选自四氢呋喃、二氯甲烷、氯仿、四氯化碳、三溴氧磷中的一种或几种的混合物；所述的还原反应合成4-溴-1,8-二氮萘所用的溶剂选自甲醇、乙醇、正丙醇、异丙醇中的一种或几种的混合物。
4.根据权利要求1的方法，其特征在于,所述的合成化合物1,8-二氮杂萘-2,4-二醇的反应温度是0℃-溶剂的回流温度；所述的溴化反应合成化合物3所用的反应温度是0℃-溶剂的回流温度；所述的还原反应合成4-溴-1,8-二氮萘的反应温度是0℃-溶剂的回流温度。
5.根据权利要求1的方法，其特征在于,所述的合成化合物1,8-二氮杂萘-2,4-二醇的反应温度是溶剂的回流温度；所述的溴化反应合成化合物3所用的反应温度是溶剂的回流温度；所述的还原反应合成4-溴-1,8-二氮萘的反应温度是室温。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610177446.0A CN107226813A (zh) | 2016-03-24 | 2016-03-24 | 一种制备4-溴-1,8-二氮萘的方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610177446.0A CN107226813A (zh) | 2016-03-24 | 2016-03-24 | 一种制备4-溴-1,8-二氮萘的方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107226813A true CN107226813A (zh) | 2017-10-03 |
Family
ID=59932572
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610177446.0A Withdrawn CN107226813A (zh) | 2016-03-24 | 2016-03-24 | 一种制备4-溴-1,8-二氮萘的方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107226813A (zh) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010017047A1 (en) * | 2008-08-05 | 2010-02-11 | Merck & Co., Inc. | Therapeutic compounds |
| CN104086543A (zh) * | 2014-06-19 | 2014-10-08 | 湖南华腾制药有限公司 | 一种制备4-氯-1,8-二氮萘的方法 |
-
2016
- 2016-03-24 CN CN201610177446.0A patent/CN107226813A/zh not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010017047A1 (en) * | 2008-08-05 | 2010-02-11 | Merck & Co., Inc. | Therapeutic compounds |
| CN104086543A (zh) * | 2014-06-19 | 2014-10-08 | 湖南华腾制药有限公司 | 一种制备4-氯-1,8-二氮萘的方法 |
Non-Patent Citations (1)
| Title |
|---|
| CZUBA, WLADYSLAW ET AL.: "Differences in the reactivity from nucleophilic substitution of halogens in position 2 and 4 of 1,8-naphthyridine", 《ZESZYTY NAUKOWE UNIWERSYTETU JAGIELLONSKIEGO, PRACE CHEMICZNE》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109311889B (zh) | 激活素受体样激酶抑制剂 | |
| WO2018022761A1 (en) | Substituted cyclopentane-amides for treating disorders related to ret | |
| JP7420403B2 (ja) | キナーゼ阻害剤として使用される化合物およびその応用 | |
| WO2019123007A1 (zh) | 芳香烃受体调节剂 | |
| Ferlin et al. | Design, synthesis, and structure–activity relationships of azolylmethylpyrroloquinolines as nonsteroidal aromatase inhibitors | |
| Zhang et al. | Convenient synthesis of novel geiparvarin analogs with potential anti-cancer activity via click chemistry | |
| WO2009010789A2 (en) | Pyrimidine derivatives 934 | |
| WO2021254005A1 (zh) | 一种免疫抑制剂、其制备方法和应用 | |
| Wei et al. | Synthesis of artemisinin-piperazine-furan ether hybrids and evaluation of in vitro cytotoxic activity | |
| El-Assaly et al. | Synthesis, molecular docking studies, and antimicrobial evaluation of pyrano2, 3-cpyrazole derivatives | |
| CN113061138A (zh) | 一种三氮唑[5,4-d]嘧啶酮三环类化合物及制备方法和用途 | |
| JP4601038B2 (ja) | インドリルマレイミド類 | |
| Khan et al. | One pot synthesis of oxygenated tri-heterocycles as anti-microbial agents | |
| CN110461849B (zh) | 一种csf1r抑制剂及其制备方法和应用 | |
| Gupta | Efficient synthesis of antifungal active 9-substituted-3-aryl-5H, 13aH-quinolino [3, 2-f][1, 2, 4] triazolo [4, 3-b][1, 2, 4] triazepines in ionic liquids | |
| Al-Tel | Design and synthesis of novel tetrahydro-2H-Pyrano [3, 2-c] Pyridazin-3 (6H)-one derivatives as potential anticancer agents | |
| CN110240593A (zh) | 取代芳胺化合物及其制备方法和用途 | |
| CN107226813A (zh) | 一种制备4-溴-1,8-二氮萘的方法 | |
| JP2021508319A (ja) | Ａｋｔ阻害剤としての塩形態及びその結晶形態 | |
| CN104086543A (zh) | 一种制备4-氯-1,8-二氮萘的方法 | |
| CN106810550A (zh) | 一种萘啶衍生物的制备方法 | |
| Harisha et al. | Base free regioselective synthesis of α-triazolylazine derivatives | |
| CN118930530A (zh) | No供体型取代香豆素-呋咱偶联物与抗肿瘤活性 | |
| CN107722001A (zh) | 一种制备3‑溴‑5‑氯‑1,8‑二氮杂萘的方法 | |
| Reddy et al. | A short and highly convergent approach for the synthesis of rutaecarpine derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20171003 |
|
| WW01 | Invention patent application withdrawn after publication |